Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Over One Quarter of Resistant Complicated Urinary Tract Infections Fail Therapy

1 hour ago 3

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

More than one in four patients diagnosed with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacterales that are nonsusceptible to fluoroquinolones or resistant to trimethoprim-sulfamethoxazole experience treatment failure within thirty days of initiating targeted antimicrobial therapy. According to a retrospective observational cohort analysis using longitudinal data from the Optum Electronic Health Record dataset between January 2018 and September 2023, the overall thirty-day cumulative incidence of treatment failure reached 27.5 percent among patients who were hospitalized at baseline and 25.2 percent among individuals managed in outpatient or non-hospitalized care environments. Across the entire cohort of 7,388 eligible adult patients evaluated across diverse medical facilities in the United States, 2,014 individuals, representing an overall proportion of 27.3 percent, met the formal composite criteria for treatment failure. The study highlights severe therapeutic challenges and high rates of clinical relapse associated with these multi-resistant gram-negative pathogens, which leave medical practitioners with exceedingly few effective oral antibiotic treatment regimens.

Complicated urinary tract infections represent a major clinical and operational burden across modern healthcare systems, with nearly three million episodes documented annually across the United States. Under the 2025 Infectious Diseases Society of America guidelines, complicated urinary tract infections are distinguished from uncomplicated acute cystitis confined strictly to the bladder by the presentation of systemic manifestations of illness, such as documented fever, bacteremia, or acute pyelonephritis, as well as catheter-associated infections. Bacterial pathogens that produce extended-spectrum beta-lactamase enzymes enzymatically hydrolyze and neutralize most penicillins, cephalosporins, and aztreonam. Because these strains frequently acquire co-resistance genes conferring non-susceptibility to fluoroquinolones and resistance to trimethoprim-sulfamethoxazole, empiric oral selections are severely constrained. Regional resistance rates across both inpatient and ambulatory clinical settings in the United States have widely surpassed the twenty-percent threshold at which guidelines recommend switching to an alternative antimicrobial drug class, forcing extensive reliance on intravenous agents to treat persistent infections.

To evaluate real-world clinical trajectories, therapeutic patterns, and patient outcomes, investigators extracted de-identified medical records from large health systems, ambulatory clinics, and private medical networks participating in the Optum electronic database. From an initial pool of 4,954,363 patients recorded throughout the nearly six-year study window, 731,660 individuals had documented diagnostic evidence of a complicated urinary tract infection. The researchers applied strict inclusion criteria requiring adult status, a positive blood or urine culture confirming extended-spectrum beta-lactamase-producing Enterobacterales exhibiting resistance to trimethoprim-sulfamethoxazole or nonsusceptibility to fluoroquinolones, and an active antibiotic prescription within seven days of the microbiological diagnostic test. Patients receiving intravenous antibiotic therapies within twenty-eight days prior to the baseline infection date were excluded to ensure that the investigation analyzed incident rather than ongoing chronic infection episodes. The final analytic population comprised 7,388 individuals whose therapeutic sequences were tracked through predefined observation periods across inpatient and outpatient care environments.

The demographic and clinical profile of the analyzed cohort demonstrated substantial baseline vulnerability, with an average age of 65.6 years and a standard deviation of 17.7 years. Women comprised 66.3 percent of the patient cohort, 76.1 percent of patients were white, and 82.2 percent were non-Hispanic, with 35.7 percent residing in the Midwestern United States and 33.8 percent maintaining dual health insurance coverage. Patients presented with a mean Quan-Charlson Comorbidity Index score of 2.3, indicating moderate chronic illness burdens across the population. Among all participants, 46.2 percent were indexed in hospital facilities while 52.5 percent were managed in non-hospital settings. Most individuals, accounting for 70.5 percent of the cohort, had their diagnosis established through diagnostic codes for acute cystitis or unspecified urinary tract infection paired with a complicating factor, while 6.8 percent had acute pyelonephritis, 9.5 percent presented with catheter-associated infections, and 14.6 percent displayed other complicated conditions.

Microbiological characterization of the 7,902 extended-spectrum beta-lactamase-producing Enterobacterales isolates recovered from the eligible cohort showed that 97.5 percent originated from urine cultures, with monomicrobial infections present in 93.4 percent of cases. Escherichia coli emerged as the primary causative uropathogen, accounting for 75.1 percent of all recovered Enterobacterales isolates, followed by Klebsiella pneumoniae at 13.4 percent and Proteus species at 6.0 percent. Antimicrobial susceptibility testing demonstrated that 81.7 percent of the isolates were nonsusceptible to fluoroquinolones, 68.0 percent were resistant to trimethoprim-sulfamethoxazole, and 2.2 percent exhibited nonsusceptibility to carbapenems.

The researchers formulated distinct operational definitions of treatment failure tailored to inpatient and outpatient care environments over a thirty-day post-index window. For outpatients, treatment failure required hospital admission or emergency department visits for urinary infection or sepsis, prescription of an alternative antibiotic with perceived beta-lactamase activity, microbiological persistence of the identical uropathogen on repeat urine culture, or all-cause mortality. Among non-hospitalized individuals, 847 of 3,362 patients, or 25.2 percent, experienced treatment failure, most commonly triggered by the prescription of an alternative antibiotic with beta-lactamase activity in 51.9 percent of failures, hospital admission or emergency visits in 27.2 percent, documented microbiological persistence in 26.8 percent, and death in 3.7 percent. For hospitalized patients, treatment failure encompassed readmission or emergency visits within thirty days post-discharge, switching to a different intravenous antibiotic between days five and thirty, altering oral or intravenous regimens after oral step-down, microbiological persistence, or death. Among 4,026 hospitalized patients, 1,167 individuals, or 29.0 percent, experienced treatment failure.

Patients who suffered treatment failure were older, with 64.2 percent aged sixty-five years or older compared with 58.7 percent among those without failure, and were more frequently male, representing 39.4 percent versus 31.6 percent. Those experiencing treatment failure presented with higher baseline Quan-Charlson Comorbidity Index scores, averaging 2.9 compared to 2.1 among non-failing counterparts. Underlying urologic abnormalities were observed in 71.7 percent of failing patients versus 64.5 percent of non-failing individuals, while diabetes was documented in 54.9 percent compared to 49.3 percent. Severe renal dysfunction was present in 43.8 percent of patients experiencing failure compared to 32.0 percent among those without failure, and baseline sepsis was identified in 16.0 percent versus 11.6 percent. Furthermore, pre-existing clinical conditions predisposing patients to adverse drug reactions were present in 22.7 percent of treatment failure cases compared to 18.2 percent among individuals without failure.

Analysis of real-world prescribing patterns uncovered tremendous therapeutic heterogeneity spanning the pre-index, index, and post-index therapeutic windows. During the week preceding baseline diagnosis, 42.0 percent of patients were prescribed an antibiotic, receiving a mean of 1.6 distinct agents, with 24.9 percent receiving intravenous therapy and 25.9 percent receiving oral agents. The mean interval from diagnosis to the start of index treatment was 3.2 days, with a median of 1.0 day. Intravenous therapy served as the index prescription for 67.9 percent of the cohort, dominated by carbapenems at 43.0 percent, third-generation cephalosporins at 25.9 percent, and penicillins at 12.2 percent. Among patients initiated on intravenous therapy, 76.9 percent started as inpatients, with 37.1 percent subsequently discharged on oral step-down antibiotics. Oral therapies accounted for 32.1 percent of index prescriptions, predominantly nitrofurantoin at 36.5 percent, beta-lactams at 19.2 percent, fluoroquinolones at 17.4 percent, and trimethoprim-sulfamethoxazole at 16.1 percent, despite confirmed in vitro resistance. Across the complete cohort, investigators identified 1,379 distinct antibiotic sequences, with the ten most common sequences accounting for only 34.6 percent of patients.

Secondary clinical outcomes documented substantial downstream medical consequences following index infection episodes. All-cause mortality reached 4.4 percent at thirty days and 6.3 percent at sixty days, with median times to death of 10.0 and 16.0 days among those who died. Sepsis developed within thirty days in 6.9 percent of the 4,855 patients at risk, occurring after a median duration of 10.0 days, while bacteremia arose in 5.3 percent of 6,566 at-risk individuals after a median of 2.0 days. Over a six-month observation window, 28.6 percent of the entire cohort experienced recurrent urinary tract infections, corresponding to an incidence rate of 0.28 infections per one hundred person-months. Recurrence occurred in 33.9 percent of patients who experienced treatment failure compared to 26.7 percent among those who did not. Among 3,973 individuals not diagnosed as inpatients, 24.5 percent required hospital admission within thirty days. For patients diagnosed as inpatients, mean hospital length of stay was 7.5 days with a median of 5.0 days, while all-cause hospital readmission rates reached 19.4 percent at thirty days, 28.2 percent at sixty days, and 34.0 percent at ninety days post-discharge.

The study authors noted several methodological considerations and clinical limitations inherent to retrospective electronic health record research. Reliance on diagnostic coding and natural language processing may have introduced diagnostic misclassification, and negative microbiology cultures were not systematically captured across all participating health systems. Because the study utilized a composite definition of treatment failure that included antibiotic switching, researchers could not independently verify the clinical rationale prompting prescription alterations, leaving open the possibility that some changes reflected empirical adjustments rather than therapeutic failure. Furthermore, mortality data derived from external death master indices may involve reporting lags of up to six months. Despite these constraints, the investigators concluded that complicated urinary tract infections caused by resistant extended-spectrum beta-lactamase-producing Enterobacterales generate high rates of therapeutic failure, frequent rehospitalization, and substantial healthcare resource utilization, demonstrating an urgent unmet clinical need for novel, highly effective oral antimicrobial options capable of supporting reliable outpatient management.

Subject of Research: Treatment patterns and clinical failure rates in resistant Enterobacterales complicated urinary tract infections

Article Title: Complicated Urinary Tract Infections Caused by Fluoroquinolone-Non-Susceptible/Trimethoprim-Sulfamethoxazole-Resistant Extended-Spectrum β-Lactamase-Producing Enterobacterales: Patient Characteristics, Resistance Phenotypes, Treatment Patterns, and Clinical Outcomes

Article References: Shields, R. K., Ackerman, A. L., Drysdale, M., Chang, R., Yu, L., DerSarkissian, M., Gillespie, I. A., Pinaire, M., Chen, Z., Duh, M. S., Farrell-Foster, A., & Mitrani-Gold, F. S. (2026). Complicated Urinary Tract Infections Caused by Fluoroquinolone-Non-Susceptible/Trimethoprim-Sulfamethoxazole-Resistant Extended-Spectrum β-Lactamase-Producing Enterobacterales: Patient Characteristics, Resistance Phenotypes, Treatment Patterns, and Clinical Outcomes. Infectious Diseases and Therapy, 15(12), 3447-3472. https://doi.org/10.1007/s40121-026-01460-y

Image Credits: AI Generated

DOI: 10.1007/s40121-026-01460-y

Keywords: Complicated urinary tract infections, Enterobacterales, Extended-spectrum beta-lactamase, Fluoroquinolone resistance, Trimethoprim-sulfamethoxazole, Treatment failure, Optum Electronic Health Record, Escherichia coli, Klebsiella pneumoniae, Carbapenems, Intravenous antibiotics, Oral step-down therapy, Hospital readmission, Infection recurrence, Antimicrobial resistance, Uropathogens, Pyelonephritis

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway